In a major blow to growth prospects, Novo Nordisk As scuttled development of levermeloxifene, a ballyhooed drug in advanced testing against osteporosis. Levormeloxifene had been viewed as the crown jewel in an aggressive research push that aimed to make Novo a powerhouse in female health care.